Press coverage about Covance (NYSE:CVD) has trended somewhat positive this week, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Covance earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave news coverage about the healthcare company an impact score of 85 out of 100, indicating that recent media coverage is very likely to have an effect on the company’s share price in the next several days.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/07/16/covance-cvd-earning-somewhat-favorable-press-coverage-study-shows.html.

Covance Company Profile

Covance Inc is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services.

Insider Buying and Selling by Quarter for Covance (NYSE:CVD)

Receive News & Stock Ratings for Covance Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covance Inc. and related stocks with our FREE daily email newsletter.